Navigation Links
NIH multicenter AIDS cohort study commemorates 25 years of discovery
Date:5/6/2009

The longest U.S. study of people with HIV/AIDS will be honored at a 25th anniversary commemoration on May 12, 2009, at the Carnegie Institution for Science in Washington, D.C. The Multicenter AIDS Cohort Study (MACS) has significantly contributed to the scientific understanding of HIV, AIDS and the effects of antiretroviral therapy through more than 1,000 publications, many of which have guided public health policy and the clinical care of people with HIV. MACS investigators prospectively study the natural and treated history of HIV infection in thousands of homosexual and bisexual men at sites in Baltimore, Chicago, Pittsburgh and Los Angeles.

Guests will hear a keynote address by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. NIAID and the National Cancer Institute developed the MACS and have been its principal sponsors.

"The MACS has been one of the most rigorous and productive epidemiologic HIV/AIDS studies in history," says Dr. Fauci. "The MACS led key studies that linked sexual behavior to HIV transmission, determined the median period of time between HIV infection and the onset of AIDS, showed that an imbalance of T-cell types precedes AIDS, and made a multitude of other pivotal discoveries that advanced HIV/AIDS research."

An extraordinary characteristic of the MACS is its 25 years of behavioral and biological data and specimens from men who have sex with men, before and after they became infected with HIV, before and after they were diagnosed with AIDS, and before and after they began highly active antiretroviral therapyalong with data from a control group of same-aged, HIV-free men who have sex with men. Comparing these before-and-after specimens and data from HIV-infected and uninfected individuals has yielded numerous seminal discoveries, including:

  • How best to diagnose HIV infection
  • The direct relationship between viral loadt
    '/>"/>

Contact: Laura Sivitz
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Johns Hopkins leads first 12-patient, multicenter domino donor kidney transplant
2. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
3. Large multicenter study suggests new genetic markers for Crohns disease
4. Minimally invasive fibroid treatment fares well in multicenter trial
5. CT Angiography Highly Accurate: Multicenter Trials Show
6. CT angiography highly accurate, multicenter trials show
7. Medical University of South Carolina Leads Multicenter Study Evaluating Biliary Sphincter Disorder
8. Decreasing access to cigarettes for youth in the Minnesota Adolescent Community Cohort Study
9. Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
10. Pitt study on alcohol reveals drinkers not only zone out -- but also are unaware that they do
11. ABCs and No Skinned Knees: Study Reveals Various Barriers to Physical Activity in Child Care
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Mayo Clinic study reveals rural, unmarried women at higher risk for depression 2Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:Chemical engineering researchers identify biofilms that cause infections 2Health News:Chemical engineering researchers identify biofilms that cause infections 3Health News:Chemical engineering researchers identify biofilms that cause infections 4Health News:Study aims to improve sex education for deaf pupils 2Health News:Study aims to improve sex education for deaf pupils 3Health News:Chair of Radiology at Presbyterian Hospital of Dallas Named President of American College of Physician Executives 2Health News:Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success 2Health News:Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success 3Health News:Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success 4